Portland, OR, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Allied Market Research recently published a report, titled, “Antibiotics Market by Class (Beta Lactam & Beta Lactamase, Quinolones, Macrolides, and Others), Drug Origin (Natural, Semisynthetic, and Synthetic), Spectrum of Activity (Broad-spectrum Antibiotic and Narrow-spectrum Antibiotic), and Route of Administration (Oral, Intravenous, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025”. According to the report, the global antibiotics market was valued at $42.34 billion in 2017 and is anticipated to reach $50.37 billion by 2025, registering a CAGR of 2.1% during the forecast period.
Growth Drivers and Industry Trends
Surge in the prevalence of infectious diseases worldwide and increased awareness & disposable income in low and middle-income countries (LMICs)[SB1] that lead to higher antibiotic consumption drive the growth of the global antibiotic market. However, the rise in antibiotic resistance as a result of antibiotic misuse along with lengthy regulatory approval period restrict market growth. Nonetheless, the discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections would provide lucrative opportunities to emerging market players in the near future.
Based on class, the quinolones segment is projected to register the highest growth rate from 2018 to 2025, due to increased demand for broad-spectrum bactericidal activity, enhanced oral bioavailability, superior tissue penetration, and improved safety & tolerability. By drug origin, the semisynthetic segment garnered the highest revenue in 2017 and is expected to continue this trend throughout the forecast period.
Request Report Sample at: https://www.alliedmarketresearch.com/request-sample/5072
Segmentation Analysis of the Industry
Based on a route of administration, the intravenous segment is expected to continue its dominance through 2025 as the major revenue contributor, due to increase in the prevalence of severe infections and on account of the fact that intravenous antibiotics are administered in higher concentrations which allows them to reach tissues faster as compared to oral antibiotics. By region, Asia-Pacific is expected to retain its dominance through 2025, on account of over-the-counter availability and increased consumption of antibiotics. However, LAMEA is projected to experience the fastest CAGR of 3.5% during the forecast period, owing to the lack of regulations that monitor antibiotic use in the region.
Industry Key Players
The key players analyzed in the report include Abbott Laboratories, Allergan Plc., F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.
About Us:
Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.